1. Home
  2. TECX vs FINS Comparison

TECX vs FINS Comparison

Compare TECX & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc. Common Stock

TECX

Tectonic Therapeutic Inc. Common Stock

HOLD

Current Price

$20.98

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Logo Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

FINS

Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

HOLD

Current Price

$13.23

Market Cap

429.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
FINS
Founded
2019
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
359.0M
429.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
FINS
Price
$20.98
$13.23
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$81.20
N/A
AVG Volume (30 Days)
407.9K
78.0K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
9.97%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$11.61
52 Week High
$61.07
$12.57

Technical Indicators

Market Signals
Indicator
TECX
FINS
Relative Strength Index (RSI) 59.16 59.17
Support Level $18.60 $12.81
Resistance Level $22.00 $13.25
Average True Range (ATR) 1.72 0.16
MACD 0.09 0.03
Stochastic Oscillator 78.88 91.30

Price Performance

Historical Comparison
TECX
FINS

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.

Share on Social Networks: